Navigation Links
Aging hepatitis C population escalates demand for liver transplantation
Date:12/6/2012

New research reveals that the greatest demand for liver transplantation due to hepatitis C (HCV)-related liver disease occurs among Americans born between 1941 and 1960. Findings in the December issue of Liver Transplantation, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD), suggest that continuing increased demand for transplantation is driven by the development of liver cancer in baby boomers with HCV, but that the demand may decrease as patients born in this time period continue to grow older.

HCV is the most common blood-borne infection and cause of liver disease requiring transplantation in the U.S., chronically infecting more than one percent of Americans. Previous studies show that among patients living with chronic HCV, 10% to 20% will develop cirrhosis and up to 5% will progress to liver cancer (hepatocellular carcinoma; HCC). Further evidence implicates HCV as the primary risk factor for developing HCC in up to 47% of cases of patients with HCC.

The peak U.S. HCV prevalence of 4% occurred in those born in 1940 through 1965, who were 20 to 30 years of age during 1979 to 1989, when HCV infection risk was at its highest. As this population ages, Davis et al. project that between 2000 and 2030 cirrhosis in patients with HCV will increase two-fold, from 472,000 to 879,000. Moreover, Wise et al. suggests HCV-related deaths will increase in Americans 55 to 64 years of age by 2004.

"The dire projections in HCV complications spurred our investigation of age-specific trends in liver transplantation demand," said lead author Dr. Scott Biggins with the University of Colorado School of Medicine in Aurora, Colo. For the present study, researchers identified all adult liver transplant candidates who were registered with the Organ Procurement and Transplantation Network (OPTN) between 1995 and 2010. Patients were then classified with the diagnosis of HCV, with or without HCC.

Results show there were 126,862 new candidates for first liver transplant registered with OPTN, with 41% of these having HCV. Candidates were categorized by birth year and found that the highest HCV frequency (in decreasing order) were those born in 1951-1955, 1956-1960, 1946-1950, and 1941-1945. These four birth groups represent 81% of all new liver transplant registrants with HCV.

Furthermore, findings indicate that between 2000 and 2010 there was a four-fold increase in new transplant candidates with HCV and HCC in the 1941 to 1960 birth cohorts. The authors anticipate an increase in the proportion of new registrants, 60 years and older, with HCV will have liver cancer.

"Over the coming decade the aging of those infected with HCV will challenge the transplant community to reconsider current treatment plans given the projected increase in liver transplantation demand, particularly from patients with HCV and liver cancer," concludes Dr. Biggins. "With the aging of the population of patients with HCV, many of these patients may not be healthy enough for transplantation and the number of liver transplants in patients with HCV may decrease."


'/>"/>

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related medicine news :

1. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
2. Social ties have mixed impact on encouraging healthy behaviors in low-income areas
3. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
4. MR enterography is as good or better than standard imaging exams for pediatric Crohns patients
5. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
6. Joslin scientists identify important mechanism that affects the aging process
7. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
8. Staging and risk stratification of thyroid cancer improved with SPECT/CT
9. Study examines necessity of additional imaging in PET/CT oncologic reports
10. Self-Managing COPD Might Pose Risks, Study Suggests
11. CNIO scientists successfully test the first gene therapy against aging-associated decline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... 11, 2016 , ... Student-doctors from Western University of Health ... Tuesday, February 9, taking one of the final steps in their medical school ... across the country. Of the 103 student-doctors who comprise the College of Osteopathic ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Image ... business to a new market, and it’s the buildings of Nashville that will benefit. ... when I needed to relocate to Nashville, there was no question that I would ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... and women’s health, is pleased to announce the promotions of Allison Kelly to ... team, Steve Catone to executive vice president of North American capital sales, and ...
(Date:2/11/2016)... Australia (PRWEB) , ... February 11, 2016 , ... ... potential ?" motivational speaker, trainer and author Ray Clarke poses a question as ... personal fulfillment . In his book, "Being in the Being" (published by Partridge ...
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... ANKENY, Iowa , 11 de fevereiro de ... a inauguração de sua fábrica de soroalbumina bovina ... Nova Zelândia. A fábrica fica na Ilha Norte ... Loop "), desenvolvido e estabelecido na fábrica da ... Iowa . O projeto e instalação dos ...
(Date:2/11/2016)... 2016 Breast Cancer Therapeutics in Asia-Pacific ... Asia-Pacific (APAC) breast cancer market will experience considerable ... 2021, at a Compound Annual Growth Rate (CAGR) of 8.5%. ... 2021 - states that the Asia-Pacific ... $1.9 billion in 2014 to $3.4 billion by 2021, at ...
(Date:2/11/2016)... , February 11, 2016 Jeffrey ... Worldwide Clinical Trials, will present at this year,s Summit for ... Hyatt Regency in Miami, FL. Zucker ... to optimize study execution, supporting SCOPE,s "Improving Site Study Activation ... place on Thursday, Feb. 25 at 11:05 a.m. ...
Breaking Medicine Technology: